Related references
Note: Only part of the references are listed.Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent
Roger G. Ptak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy
J. Reutenauer et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Emerging drugs for hepatitis C
Vincent Soriano et al.
EXPERT OPINION ON EMERGING DRUGS (2008)
The cyclophilin inhibitor debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus
Robert Flisiak et al.
HEPATOLOGY (2008)
Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro
Feng Yang et al.
JOURNAL OF VIROLOGY (2008)
Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy
Douglas P. Millay et al.
NATURE MEDICINE (2008)
Current and future management of chronic hepatitis C infection
T. J. S. Cross et al.
POSTGRADUATE MEDICAL JOURNAL (2008)
Sensitivity of hepatitis C virus to cyclosporine a depends on nonstructural proteins NS5A and NS5B
Fiona Fernandes et al.
HEPATOLOGY (2007)
Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy
Koichi Watashi et al.
REVIEWS IN MEDICAL VIROLOGY (2007)
Characterization of hepatitis c virus subgenomic replicon resistance to cyclosporine in vitro
John M. Robida et al.
JOURNAL OF VIROLOGY (2007)
Epidemiology of hepatitis C virus infection
Miriam J. Alter
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo
Kazuaki Inoue et al.
HEPATOLOGY (2007)
SCH 503034, a novel hepatitis C virus pro-tease inhibitor, plus pegylated interferon α-2b for genotype 1 nonresponders
Christoph Sarrazin et al.
GASTROENTEROLOGY (2007)
Mitochondrial dysfunction in the pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with cyclosporins
Alessia Angelin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Rapid decline of viral RNA in hepatitis C patients treated with VX-950: A phase Ib, placebo-controlled, randomized study
Hendrik W. Reesink et al.
GASTROENTEROLOGY (2006)
The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro
J Paeshuyse et al.
HEPATOLOGY (2006)
American Gastroenterological Association technical review on the management of hepatitis C
JL Dienstag et al.
GASTROENTEROLOGY (2006)
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes
P Simmonds et al.
HEPATOLOGY (2005)
Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins
M Nakagawa et al.
GASTROENTEROLOGY (2005)
Enterohepatic transport of bile salts and genetics of cholestasis
C Pauli-Magnus et al.
JOURNAL OF HEPATOLOGY (2005)
Hematologic side effects of interferon and ribavirin therapy
KV Kowdley
JOURNAL OF CLINICAL GASTROENTEROLOGY (2005)
Global epidemiology of hepatitis C virus infection
CW Shepard et al.
LANCET INFECTIOUS DISEASES (2005)
The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria
MJ Hansson et al.
JOURNAL OF BIOENERGETICS AND BIOMEMBRANES (2004)
Clinical guidelines on the management of hepatitis C
JCL Booth et al.
GUT (2001)
Share Paper
